Adrenocortical carcinoma radiation therapy

Jump to navigation Jump to search

Adrenocortical carcinoma Microchapters


Patient Information


Historical Perspective




Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis



History and Symptoms

Physical Examination

Laboratory Findings

X Ray




Other Imaging Studies

Other Diagnostic Studies


Medical Therapy


Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma radiation therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Adrenocortical carcinoma radiation therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma radiation therapy

CDC on Adrenocortical carcinoma radiation therapy

Adrenocortical carcinoma radiation therapy in the news

Blogs on Adrenocortical carcinoma radiation therapy

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma radiation therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Mohammed Abdelwahed M.D[3]


Radiation therapy and radiofrequency ablation may be used for palliation in patients who are not surgical candidates. Recurrence is lower in patients with adjuvant radiotherapy than in patients without radiotherapy. ACC with metastasis to bone experienced adequate pain relief after radiotherapy.

Radiation Therapy

Radiotherapy has shown improvement in both the adjuvant and palliative ACCs.

Radiation therapy in non-metastatic ACC

  • According to the National Cancer Data Base and the surveillance, epidemiology, and end results program, there is an evidence that radiotherapy might be effective.[1]
  • Local recurrence-free survival was 86% in the group that received radiation compared with 11% in those that did not.[2]
  • Radiotherapy also can be used for treating unresectable masses.[3]

Radiation therapy for palliation


  1. Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H; et al. (2006). "Outcomes of adrenal cortical carcinoma in the United States". Surgery. 140 (6): 914–20, discussion 919-20. doi:10.1016/j.surg.2006.07.035. PMID 17188138.
  2. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M; et al. (2006). "Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma". J Clin Endocrinol Metab. 91 (11): 4501–4. doi:10.1210/jc.2006-1007. PMID 16895957.
  3. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E (2011). "Adjuvant and definitive radiotherapy for adrenocortical carcinoma". Int J Radiat Oncol Biol Phys. 80 (5): 1477–84. doi:10.1016/j.ijrobp.2010.04.030. PMID 20675074.
  4. Markoe AM, Serber W, Micaily B, Brady LW (1991). "Radiation therapy for adjunctive treatment of adrenal cortical carcinoma". Am J Clin Oncol. 14 (2): 170–4. PMID 1709336.
  5. Thacker PG, Friese JL, Loe M, Biegler P, Larson M, Andrews J (2009). "Embolization of nonliver visceral tumors". Semin Intervent Radiol. 26 (3): 262–9. doi:10.1055/s-0029-1225667. PMC 3036499. PMID 21326571.
  6. de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A; et al. (2010). "Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization". Ann Surg Oncol. 17 (8): 2081–9. doi:10.1245/s10434-010-0979-2. PMID 20237856.

Template:WikiDoc Sources